 2  All items are shown before exceptional  items which were £nil (2016: £0.4 million)  and amortisation of acquired intangible  assets which, in 2017, were £0.1 million  (2016: £0.2 million) as defined in the  Financial Review. 3  Operating cash flow is arrived at by  taking the operating profit for the period  before exceptional items of £nil million  (2016: £0.4 million), depreciation,  amortisation, working capital movements  and other non cash items. 5  Data supplied by Global  Healthcare Exchange. Company Overview Strategic Report Governance Financial Statements 01 Advanced Medical Solutions Group plc Annual Report 2017 Creating quality outcomes for the global   surgical and advanced woundcare markets  through quality respected brands Our addressable market is large and growing. Chairman’s Statement 1   All items are shown before amortisation of acquired intangible assets  which, in 2017, was £0.1 million (2016: £0.2 million) as defined in the  financial review and before exceptional costs which were £nil million  (2016: £0.4 million). AMS continues to progress as a leading international provider of high quality, high value,  innovative and technologically advanced products for the surgical and advanced wound  care markets. We are pleased to report another year of strong revenue growth, profit  performance and cash generation. As reported at the half year, at the beginning of 2017 we reviewed our business  structure and consolidated our Business Units from four to two. Our Branded Business  Unit focuses on the distribution, marketing and innovation of all the Group’s branded  products. Good progress has been made with all of our brands. Revenue from our RESORBA ®  brands grew  steadily across all territories and has grown by 15% and by 6% at constant currency  to £20.8 million (2016: £18.1 million), while ActivHeal ®  grew by 4% to £6.3 million  (2016: £6.0 million). Under this agreement, we receive  royalties from Organogenesis’